Contact Media

If you have any questions, please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices

Contact Media Relations

Xultophy® (IDegLira) receives positive opinion from EMA

25 July - The Committee for Medicinal Products for Human Use (CHMP) under EMA has adopted a positive opinion recommending marketing authorisation for Xultophy® for the treatment of type 2 diabetes mellitus in adults. “We are excited about the positive opinion for Xultophy®. We believe that Xultophy® represents a new treatment paradigm with the potential to transform how type 2 diabetes is treated. We look forward to making the product available to people with type 2 diabetes in Europe,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer.

Read the company announcement

Cities Changing Diabetes

Launch in Mexico

28 March - Novo Nordisk today announces the launch of 'Cities Changing Diabetes', an ambitious new partnership programme to fight the urban diabetes challenge. The 'Cities Changing Diabetes' programme will first be launched in Mexico City with other cities in North America, Europe and Asia soon to follow. "The global diabetes epidemic is an emergency in slow motion," says Lars Rebien Sørensen, chief executive officer, Novo Nordisk. "While there are many factors fuelling the growth trajectory of diabetes, the most striking contributor is urbanisation and the growth of cities. The 'Cities Changing Diabetes' programme is our call to arms for people around the world to work together to tackle this for the long-term."

Read about the full programme

See the multimedia news release

Analysis: 6,000 new jobs in Novo Nordisk create a further 15,000 jobs in Denmark

11 June - A new analysis will be presented by Novo Nordisk today at the ‘Invitation to growth – a road to job creation’ conference in Bagsværd, Denmark. Executive Vice President and Chief Science Officer Mads Krogsgaard Thomsen: “With the expectation of creating 6,000 new jobs in Denmark over the coming years, it will be crucial for Novo Nordisk that Denmark educates world-class graduates but also focuses far more intently on attracting international talent,” says Read the full analysis in Danish (English version will follow shortly) - and read the press release.

Clinical Trial Transparency

1 March - Novo Nordisk has made it easier for external researchers to get access to clinical trial data. You may read about how we conduct our clinical trials, about volunteering to participate, how we disclose trial information to the public and how researchers can access clinical trial datasets.
Read more about clinical trials.


Financial results Q2




Team Novo Nordisk racing

July - Team Novo Nordisk, the world’s first all-diabetes professional cycling team, will race in Tour of Denmark 2014, 6-10 August. Learn about the team’s mission to educate, empower and inspire those affected by diabetes and follow the team results on facebook and twitter.

TBL Quarterly

24 June - What is the key to better health in India? Read the stories in the new TBL Quarterly.  

Changing Diabetes in India

11 June - In India, there are not enough healthcare professionals to meet the needs of the 65 million people with diabetes. Partnerships can change this. Find out how (PDF) 

Novo Nordisk Stories